Company Information
GeneMedicine CO., Ltd., is a company specializing in the development of oncolytic virus through state-of-the-art genetic engineering. The founder Chae-Ok Yun has been researching and developing oncolytic virus for more than 25 years, and founded GeneMedicine to deliver cutting-edge and state-of-the-art oncolytic virus into clinics around the world. GeneMedicine CO., Ltd., holds multiple patent rights in technologies endowing and improving cancer specificity of oncolytic virus and anticancer therapeutic transgene candidates that had been utilized to develop next generation oncolytic viruses. Notably, our company has developed and patented a nanomaterial-based platform technology that allows efficient and tumor-targeted delivery of oncolytic virus by systemic administration. Based on these innovations, currently one pipeline (GM101) has completed phase 1 clinical trial and further clinical development is underway, aiming for drug approval by 2024. Two other pipelines (GM103, GM102) will begin their respective clinical trial in 2021 and 2022. As of July 2020, 96 international patents and 47 domestic patents for the abovementioned technological innovations have been registered while 134 international patents and 64 domestic patents have been filed. The major pipelines are protected under multiple patents spanning different technological components of individual pipeline that were utilized during the development process, thus ensuring high level of protection against any potential patent infringement by third party. As a testament to technological prowess of our firm and our product, we have successfully completed two licensing-out deals with US-based biocompany in 2016 and secured Series A funding of 13.9 million USD in 2019. The company is also actively partaking in number of high profile domestic grants for research & development as well as business development. With these funds, the company has hired experts that are well-suited for the clinical development of next
